Physician profile
Abdullah Mohammad Khan
NPI 1831475292
$23,468.30
in general payments reported to CMS, 2019-2025
8 companies · $12K in 2025
The $12K reported for 2025 was more than what 79% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $1,100 · 2022: $3,416 · 2024: $6,388 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $3,060 · Consulting Fee: $1,840 · Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,222.00 |
| Travel and Lodging | $3,060.15 |
| Consulting Fee | $1,840.00 |
| Food and Beverage | $445.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $12,237.86 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $5,674.49 | 2024-2025 | Abecma |
| Amgen INC. | $2,337.50 | 2020-2022 | |
| Janssen Biotech, INC. | $1,685.90 | 2025 | Darzalex |
| Celgene Corporation | $1,468.25 | 2019-2024 | Pomalyst |
| Adaptive Biotechnologies Corporation | $64.30 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.